Title: Fosfomycin: Current Scenario and Susceptibility Pattern in Urinary Isolates of a Teaching Hospital
Author: Siddiqui AH
DOI: https://dx.doi.org/10.18535/jmscr/v6i6.70
Abstract
The increasing resistance among Gram Negative organisms has demanded the implementation of alternative treatment strategies. With no other options in the near future we are re-evaluating the older antibiotics which at that point of time were discontinued because of the associated side effects. This study was undertaken to know the susceptibility pattern of urinary isolates in our hospital.
Material and Methods: This study was done on all the urinary isolates obtained from January 2017 to June 2017. Samples were processed and interpretated as per CLSI guideline. The isolates included for this study are, E coli, Klebsiellasp and Pseudomonas sp.
Results: A total of 230 significant isolates were obtained from 1732 urine samples. The most common isolate obtained was E coli with a sensitivity of 85%. Isolates obtained from admitted patients had lesser sensitivity.
Conclusion: This study shows that fosfomycin could be used as an alternative treatment modality. Combination therapy if used can help in reducing development of resistance.
Keywords: Multi drug resistance organisms, fosfomycin, Urinary Tract infection.
References
- Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin resistant enterococci. J Antimicrob Chemother. 1999;43:211-17.
- Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E, Falagas ME. Susceptibility of urinary tract bacteria to fosfomycin. Antimicrob Agents Chemother 2009;53:4508-10.
- Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum blactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50
- Pfausler, B.; Spiss, H.; Dittrich, P.; Zeitlinger, M.; Schmutzhard, E.; Joukh-adar, C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. Antimicrob. Chemother.2004, 53, 848–852.
- Frossard, M.; Joukhadar, C.; Erovic, B.M.; Dittrich, P.; Mrass, P.E.; van Houte, M.; Burgmann, H.; Georgopoulos, A.; Müller, M. Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues. Agents Chemother. 2000, 44, 2728–2732.
- Matzi, V.; Lindenmann, J.; Porubsky, C.; Kugler, S.A.; Maier, A.; Dittrich, P.; Smolle- Jüttner, F.M.; Joukhadar, C. Extracellular concentrations of fosfomycin in lung tissue of septic patients. Antimicrob. Chemother. 2010, 65, 995–998.
- Joukhadar, C.; Klein, N.; Dittrich, P.; Zeitlinger, M.; Geppert, A.; Skhirtladze, K.; Frossard, M.; Heinz, G.; Müller, M. Target site penetration of fosfomycin in critically ill patients. Antimicrob. Chemother. 2003, 51, 1247–1252.
- Sauermann, R.; Karch, R.; Langenberger, H.; Kettenbach, J.; Mayer-Helm, B.; Petsch, M.; Wagner, C.; Sautner, T.; Gattringer, R.; Karanikas, G.; et al. Anti-biotic abscess penetration: Fosfomycin levels measured in pus and simulated concentration-time profiles. Agents Chemother. 2005, 49, 4448–4454.
- Saiprasad P V, Krishnaprasad K. Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections. Indian J Med Microbiol 2016;34:416-20
- Dijkmans AC et al Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics2017, 6, 24; https://doi.org/10.3390/antibiotics6040024
- Kahan FM, Kahan JS, Cassidy PJ, et al. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974; 235: 364-86
- Zafar H, Noor N, Bukhari KT, Humayun S, Lakhnana NK. Antimicrobial Suscept-ibility Pattern of Fosfomycin in Various Clinical Isolates. UKJPB. 2017;5: 45-49.
- Mittal S, Sharma M, Chaudhary U. Fosfomycin use in multi-drug resistant uropathogenicEscherichia coli. Infect Disord Drug Targets 2015;15:196-201
- Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Indian J Urol 2017;33:149-54
- Sabharwal ER, Sharma R. Fosfomycin: An alternative therapy for the treatment of UTI amidst escalating antimicrobial resistance. J Clin Diagn Res 2015;9:DC06
- Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. 2016. Fosfomycin. Clin Microbiol Rev 29:321–347 doi:1128/CMR.00068-15.
- Grabein B; Graninger W; Rodríguez Baño J; Dinh A; Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017; 23:363-372
- Sano S, Karino K, Nakano K, Watanabe T, Masahiro H. [Comparative study of the efficacy on fosfomycin Na and sulbenicilin Na against the chronic urinary tract infections by Pseudomonas aeruginosa and Proteus vulgaris]. Acta UrolJpn 1979;25
- Hirsch EB, Zucchi PC, Chen A, et al. Susceptibility of multidrug-resistant Gram-negative urine isolates to oral antibiotics. Antimicrob Agents Chemother. 2016; 60:3138–3140. doi: 10.1128/AAC.02961-15.